Use of medications to reduce risk for primary breast cancer: A systematic review for the U.S. preventive services task force

Heidi Nelson, M. E Beth Smith, Jessica C. Griffin, Rongwei (Rochelle) Fu

Research output: Contribution to journalArticle

113 Citations (Scopus)

Abstract

Background: Medications to reduce risk for primary breast cancer are recommended for women at increased risk; however, use is low. Purpose: To update evidence about the effectiveness and adverse effects of medications to reduce breast cancer risk, patient use of such medications, and methods for identifying women at increased risk for breast cancer. Data Sources: MEDLINE and Cochrane databases (through 5 De-cember 2012), Scopus, Web of Science, clinical trial registries, and reference lists. Study Selection: English-language randomized trials of medication effectiveness and adverse effects, observational studies of adverse effects and patient use, and diagnostic accuracy studies of risk assessment. Data Extraction: Investigators independently extracted data on participants, study design, analysis, follow-up, and results, and a second investigator confirmed key data. Investigators independently dual-rated study quality and applicability using established criteria. Data Synthesis: Seven good-and fair-quality trials indicated that tamoxifen and raloxifene reduced incidence of invasive breast can-cer by 7 to 9 cases in 1000 women over 5 years compared with placebo. New results from STAR (Study of Tamoxifen and Ralox-ifene) showed that tamoxifen reduced breast cancer incidence more than raloxifene by 5 cases in 1000 women. Neither reduced breast cancer-specific or all-cause mortality rates. Both reduced the inci-dence of fractures, but tamoxifen increased the incidence of throm-boembolic events more than raloxifene by 4 cases in 1000 women. Tamoxifen increased the incidence of endometrial cancer and cat-aracts compared with placebo and raloxifene. Trials provided limited and heterogeneous data on medication adherence and persistence. Many women do not take tamoxifen because of associated harms. Thirteen risk-stratification models were modest predictors of breast cancer. Limitation: Data on mortality and adherence measures and for women who are nonwhite, are premenopausal, or have comorbid conditions were lacking. Conclusion: Medications reduced the incidence of invasive breast cancer and fractures and increased the incidence of thromboem-bolic events. Tamoxifen was more effective than raloxifene but also increased the incidence of endometrial cancer and cataracts. Use is limited by adverse effects and inaccurate methods to identify candidates.

Original languageEnglish (US)
Pages (from-to)604-614
Number of pages11
JournalAnnals of Internal Medicine
Volume158
Issue number8
DOIs
StatePublished - Apr 16 2013

Fingerprint

Advisory Committees
Tamoxifen
Breast Neoplasms
Incidence
Medication Adherence
Research Personnel
Endometrial Neoplasms
Placebos
Mortality
Information Storage and Retrieval
MEDLINE
Cataract
Observational Studies
Registries
Cats
Breast
Language
Raloxifene Hydrochloride
Clinical Trials
Databases

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Use of medications to reduce risk for primary breast cancer : A systematic review for the U.S. preventive services task force. / Nelson, Heidi; Smith, M. E Beth; Griffin, Jessica C.; Fu, Rongwei (Rochelle).

In: Annals of Internal Medicine, Vol. 158, No. 8, 16.04.2013, p. 604-614.

Research output: Contribution to journalArticle

@article{6eb57d5d4cfd4e5888282690f52c51df,
title = "Use of medications to reduce risk for primary breast cancer: A systematic review for the U.S. preventive services task force",
abstract = "Background: Medications to reduce risk for primary breast cancer are recommended for women at increased risk; however, use is low. Purpose: To update evidence about the effectiveness and adverse effects of medications to reduce breast cancer risk, patient use of such medications, and methods for identifying women at increased risk for breast cancer. Data Sources: MEDLINE and Cochrane databases (through 5 De-cember 2012), Scopus, Web of Science, clinical trial registries, and reference lists. Study Selection: English-language randomized trials of medication effectiveness and adverse effects, observational studies of adverse effects and patient use, and diagnostic accuracy studies of risk assessment. Data Extraction: Investigators independently extracted data on participants, study design, analysis, follow-up, and results, and a second investigator confirmed key data. Investigators independently dual-rated study quality and applicability using established criteria. Data Synthesis: Seven good-and fair-quality trials indicated that tamoxifen and raloxifene reduced incidence of invasive breast can-cer by 7 to 9 cases in 1000 women over 5 years compared with placebo. New results from STAR (Study of Tamoxifen and Ralox-ifene) showed that tamoxifen reduced breast cancer incidence more than raloxifene by 5 cases in 1000 women. Neither reduced breast cancer-specific or all-cause mortality rates. Both reduced the inci-dence of fractures, but tamoxifen increased the incidence of throm-boembolic events more than raloxifene by 4 cases in 1000 women. Tamoxifen increased the incidence of endometrial cancer and cat-aracts compared with placebo and raloxifene. Trials provided limited and heterogeneous data on medication adherence and persistence. Many women do not take tamoxifen because of associated harms. Thirteen risk-stratification models were modest predictors of breast cancer. Limitation: Data on mortality and adherence measures and for women who are nonwhite, are premenopausal, or have comorbid conditions were lacking. Conclusion: Medications reduced the incidence of invasive breast cancer and fractures and increased the incidence of thromboem-bolic events. Tamoxifen was more effective than raloxifene but also increased the incidence of endometrial cancer and cataracts. Use is limited by adverse effects and inaccurate methods to identify candidates.",
author = "Heidi Nelson and Smith, {M. E Beth} and Griffin, {Jessica C.} and Fu, {Rongwei (Rochelle)}",
year = "2013",
month = "4",
day = "16",
doi = "10.7326/0003-4819-158-8-201304160-00005",
language = "English (US)",
volume = "158",
pages = "604--614",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "8",

}

TY - JOUR

T1 - Use of medications to reduce risk for primary breast cancer

T2 - A systematic review for the U.S. preventive services task force

AU - Nelson, Heidi

AU - Smith, M. E Beth

AU - Griffin, Jessica C.

AU - Fu, Rongwei (Rochelle)

PY - 2013/4/16

Y1 - 2013/4/16

N2 - Background: Medications to reduce risk for primary breast cancer are recommended for women at increased risk; however, use is low. Purpose: To update evidence about the effectiveness and adverse effects of medications to reduce breast cancer risk, patient use of such medications, and methods for identifying women at increased risk for breast cancer. Data Sources: MEDLINE and Cochrane databases (through 5 De-cember 2012), Scopus, Web of Science, clinical trial registries, and reference lists. Study Selection: English-language randomized trials of medication effectiveness and adverse effects, observational studies of adverse effects and patient use, and diagnostic accuracy studies of risk assessment. Data Extraction: Investigators independently extracted data on participants, study design, analysis, follow-up, and results, and a second investigator confirmed key data. Investigators independently dual-rated study quality and applicability using established criteria. Data Synthesis: Seven good-and fair-quality trials indicated that tamoxifen and raloxifene reduced incidence of invasive breast can-cer by 7 to 9 cases in 1000 women over 5 years compared with placebo. New results from STAR (Study of Tamoxifen and Ralox-ifene) showed that tamoxifen reduced breast cancer incidence more than raloxifene by 5 cases in 1000 women. Neither reduced breast cancer-specific or all-cause mortality rates. Both reduced the inci-dence of fractures, but tamoxifen increased the incidence of throm-boembolic events more than raloxifene by 4 cases in 1000 women. Tamoxifen increased the incidence of endometrial cancer and cat-aracts compared with placebo and raloxifene. Trials provided limited and heterogeneous data on medication adherence and persistence. Many women do not take tamoxifen because of associated harms. Thirteen risk-stratification models were modest predictors of breast cancer. Limitation: Data on mortality and adherence measures and for women who are nonwhite, are premenopausal, or have comorbid conditions were lacking. Conclusion: Medications reduced the incidence of invasive breast cancer and fractures and increased the incidence of thromboem-bolic events. Tamoxifen was more effective than raloxifene but also increased the incidence of endometrial cancer and cataracts. Use is limited by adverse effects and inaccurate methods to identify candidates.

AB - Background: Medications to reduce risk for primary breast cancer are recommended for women at increased risk; however, use is low. Purpose: To update evidence about the effectiveness and adverse effects of medications to reduce breast cancer risk, patient use of such medications, and methods for identifying women at increased risk for breast cancer. Data Sources: MEDLINE and Cochrane databases (through 5 De-cember 2012), Scopus, Web of Science, clinical trial registries, and reference lists. Study Selection: English-language randomized trials of medication effectiveness and adverse effects, observational studies of adverse effects and patient use, and diagnostic accuracy studies of risk assessment. Data Extraction: Investigators independently extracted data on participants, study design, analysis, follow-up, and results, and a second investigator confirmed key data. Investigators independently dual-rated study quality and applicability using established criteria. Data Synthesis: Seven good-and fair-quality trials indicated that tamoxifen and raloxifene reduced incidence of invasive breast can-cer by 7 to 9 cases in 1000 women over 5 years compared with placebo. New results from STAR (Study of Tamoxifen and Ralox-ifene) showed that tamoxifen reduced breast cancer incidence more than raloxifene by 5 cases in 1000 women. Neither reduced breast cancer-specific or all-cause mortality rates. Both reduced the inci-dence of fractures, but tamoxifen increased the incidence of throm-boembolic events more than raloxifene by 4 cases in 1000 women. Tamoxifen increased the incidence of endometrial cancer and cat-aracts compared with placebo and raloxifene. Trials provided limited and heterogeneous data on medication adherence and persistence. Many women do not take tamoxifen because of associated harms. Thirteen risk-stratification models were modest predictors of breast cancer. Limitation: Data on mortality and adherence measures and for women who are nonwhite, are premenopausal, or have comorbid conditions were lacking. Conclusion: Medications reduced the incidence of invasive breast cancer and fractures and increased the incidence of thromboem-bolic events. Tamoxifen was more effective than raloxifene but also increased the incidence of endometrial cancer and cataracts. Use is limited by adverse effects and inaccurate methods to identify candidates.

UR - http://www.scopus.com/inward/record.url?scp=84876392510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876392510&partnerID=8YFLogxK

U2 - 10.7326/0003-4819-158-8-201304160-00005

DO - 10.7326/0003-4819-158-8-201304160-00005

M3 - Article

C2 - 23588749

AN - SCOPUS:84876392510

VL - 158

SP - 604

EP - 614

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 8

ER -